Across TCGA pan-cancer cohorts, RNU6-260P RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated RNU6-260P data layer.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RNU6-260P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-260P expression acts as an unfavorable survival marker, although some lineages such as LAML and ESCA show a favorable association.
BLCA, TGCT, and LAML are the cancer types where RNU6-260P RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.